Abbott Laboratories (ABT) Reported Strong One Year Amulet 360 Trial Results
Abbott Laboratories (ABT) announced strong one-year VERITAS trial results for its Amulet 360 Left Atrial Appendage Occluder, showing high closure rates and low complications in non-valvular atrial fibrillation patients. This data strengthens Abbott's position in electrophysiology and structural heart devices, reinforcing its growth narrative despite broader nutritional and margin pressures. The company awaits FDA approval for Amulet 360 in the U.S. while the device is already CE marked in Europe.
Put this headline into context
Use TradingAgents AI to connect the story to the company's filings, fundamentals, market structure, competing bull and bear arguments, and risk review.
Headlines and excerpts belong to the original publisher. Ticker associations are informational and may be incomplete. Market news is not personalized financial advice.